IQVIA Holdings Inc. $IQV Shares Bought by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP significantly increased its position in IQVIA Holdings, buying an additional 22,751 shares and raising its holdings by 232.4% during Q1, now totaling 32,542 shares valued at approximately $5.7 million.
• Several institutional investors have also made notable adjustments to their holdings in IQVIA, contributing to a combined institutional ownership of 89.62% of the company's stock.
• Despite recent insider stock sales, equities analysts maintain a positive outlook on IQVIA, with a consensus rating of "Moderate Buy" and an average target price increase to $228.62.

Wellington Management Group LLP lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 232.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,542 shares of the medical research company's stock after buying an additional 22,751 shares during the quarter. Wellington Management Group LLP's holdings in IQVIA were worth $5,737,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Pacer Advisors Inc. lifted its stake in IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after purchasing an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in IQVIA by 211.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock worth $189,691,000 after purchasing an additional 655,153 shares during the last quarter. Nuveen LLC purchased a new stake in IQVIA during the first quarter worth approximately $76,328,000. Finally, Cadian Capital Management LP purchased a new stake in IQVIA during the fourth quarter worth approximately $78,604,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Evercore ISI boosted their target price on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Truist Financial boosted their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Stock Performance

Shares of IQVIA stock traded up $1.98 during trading hours on Friday, hitting $190.71. 1,088,094 shares of the company were exchanged, compared to its average volume of 1,259,940. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The business has a 50-day moving average of $177.04 and a 200-day moving average of $167.51. The stock has a market capitalization of $32.42 billion, a price-to-earnings ratio of 27.60, a P/E/G ratio of 2.09 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the business earned $2.64 earnings per share. The company's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.